Stephen Berenson
CIK: 0001760671
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Seres Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jul 8, 2026MCRB
Seres Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
6.5K shares- - Jul 1, 2026MCRB
Seres Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
7.5K shares- - Jul 1, 2025MCRB
Seres Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
11.5K shares- - Apr 10, 2025MCRB
Seres Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
100K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 8, 2026 | MCRB Seres Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 6,500 | - | - | Direct |
| Jul 1, 2026 | MCRB Seres Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 7,508 | - | - | Direct |
| Jul 1, 2025 | MCRB Seres Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 11,470 | - | - | Direct |
| Apr 10, 2025 | MCRB Seres Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 100,000 | - | - | Direct |
1-4 of 4 transactions
About Berenson Stephen
Berenson Stephen (SEC CIK 0001760671) files insider reports with the SEC as Director of Seres Therapeutics, Inc. (MCRB).
Signal8 holds 4 ownership filings by Berenson Stephen, all Form 4s, filed between Apr 11, 2025 and Jul 10, 2026. Those filings report 4 transactions, from Apr 10, 2025 to Jul 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Berenson Stephen's filings is in CAMBRIDGE, MA.
Recent filings by Berenson Stephen
- Jul 8, 2026: Grant or award of MCRB derivative securities (Form 4, code A).
- Jul 1, 2026: Grant or award of MCRB derivative securities (Form 4, code A).
- Jul 1, 2025: Grant or award of MCRB derivative securities (Form 4, code A).
- Apr 10, 2025: Grant or award of MCRB derivative securities (Form 4, code A).